Article
Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
BMC infectious diseases - 31 Aug 2004
Santos Eneida A, Sucupira Michel V F, Arabe Juçara, Gomes Selma A
Abstract excerpt
BACKGROUND: Lamivudine inhibits replication of both human immunodeficiency virus (HIV) and hepatitis B virus (HBV) and is commonly used as part of antiretroviral therapy. The main limitation in the use of lamivudine is resistant mutation selection. Most of these mutations affect the YMDD motif of the HBV DNA polymerase. The resistance occurs through M550V or M550I aminoacid replacements. The M550V variation may...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.